Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Completed

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.

Key facts

Study ID

NCT01472627

Run by

Dana-Farber Cancer Institute

People needed

11

Starts

2010-10-01

Expected to finish

2018-01-01

Last updated by the study team

2018-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed multiple myeloma
• Therapy with bortezomib alone or bortezomib/dexamethasone being initiated as the standard of care therapy for myeloma by their treating physician

You may not qualify if…

• Hypersensitivity to bortezomib, boron or mannitol
• Treatment with other investigational drugs within 28 days before enrollment
• Diagnosed or treated for another malignancy within 6 months of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
• Use of other myeloma directed therapy (except for dexamethasone) in combination with bortezomib

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.